GlassScriptPhysician profile
Vinni Makin
NPI 1427233675
$19,489.50
in general payments reported to CMS, 2019-2025
12 companies · $2,358 in 2025
The $2,358 reported for 2025 was more than what 79% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,240 · 2020: $38.59 · 2021: $380 · 2022: $11K · 2023: $2,704 · 2024: $649 · 2025: $2,358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,196 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,174 · Food and Beverage: $736 · Travel and Lodging: $605.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,196.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,174.00 |
| Food and Beverage | $736.12 |
| Travel and Lodging | $604.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $13,541.71 | 2022-2023 | |
| Novo Nordisk INC | $4,922.90 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $333.00 | 2021 | |
| Lilly USA, LLC | $318.70 | 2019-2024 | Zepbound, Jardiance |
| Averitas Pharma INC. | $185.90 | 2024 | Qutenza |
| Sanofi-Aventis U.S. LLC | $55.13 | 2019-2020 | |
| Corcept Therapeutics | $44.50 | 2024-2025 | Korlym |
| Medtronic, INC. | $26.72 | 2024 | Minimed 780g |
| Antares Pharma, INC. | $17.63 | 2023 | Xyosted, Tlando, Nocdurna |
| Astrazeneca Pharmaceuticals LP | $17.40 | 2021 | |
| Vivus LLC | $13.58 | 2021 | |
| Xeris Pharmaceuticals, INC. | $12.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinni Makin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.